Review the trend for a client receiving lacosamide and select the best interpretation and action.
Trend
Choose your responses, then check the answer.
Explanation
Progressive PR prolongation, bradycardia, dizziness, and near-syncope after lacosamide escalation—especially with another atrioventricular-node-slowing drug—require holding the dose, ECG evaluation, and prompt prescriber notification.
Quick answer Treat worsening conduction plus symptoms as a lacosamide safety signal.
Why this is correct Lacosamide can prolong the PR interval and has been associated with bradycardia and atrioventricular block. Risk increases with underlying conduction disease or concomitant drugs that affect cardiac conduction.
Easy analogy or mental picture Build a medication-safety chain: identify the new cue, connect it to the drug mechanism or labeled limitation, stop preventable exposure, stabilize the client, and verify a measurable response.
Memory hook Drug, urgent cue, protective action, and reassessment endpoint.
NCLEX decision rule Choose the action that prevents the most immediate medication-related harm while preserving indicated treatment and required monitoring.
Why the other choices are wrong Options that continue a suspect exposure, normalize a labeled danger cue, substitute an unauthorized dose, or delay escalation leave the client at risk.
References
1DailyMed: VIMPAT (lacosamide)PR-interval prolongation, bradycardia and atrioventricular block risk, ECG monitoring, and additive conduction effects
Medication-safety reviewVerify indication, current assessment, dose and route, organ function, interactions, urgent toxicity cues, authorized action, and measurable follow-up.